CALA - Calithera Biosciences - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

250.2K

Cash

25.45M

Avg Qtr Burn

-10.9M

Short % of Float

8.92%

Insider Ownership

1.07%

Institutional Own.

26.77%

Qtr Updated

12/31/22

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
CB-1158 (INCB00158) (Arginase Inhibitor) Details Solid tumors	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CB-839 (Glutaminase Inhibitor Telaglenastat) Details Colorectal cancer , Pancreatic cancer, Non-small cell lung carcinoma	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CB-839 (Glutaminase Inhibitor Telaglenastat) Details Non-small cell lung carcinoma, Solid tumor/s	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CB-839 (Glutaminase Inhibitor Telaglenastat) Details Renal cell carcinoma	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CB-659 (mivavotinib) Details Non-Hodgkin lymphoma, Diffuse large B cell lymphoma	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CB-839 (Glutaminase Inhibitor Telaglenastat) Details Renal cell carcinoma, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.